Prednisolone is not recommended for fatty liver disease and may actually worsen the condition. Fatty liver disease, or hepatic steatosis, occurs when excess fat accumulates in liver cells, affecting approximately one in three UK adults. Whilst prednisolone is an effective anti-inflammatory medication for conditions such as asthma and rheumatoid arthritis, its metabolic effects—including promoting insulin resistance, fat synthesis, and elevated blood sugar—directly counteract the therapeutic goals for managing fatty liver. Current evidence-based treatment focuses on lifestyle modification, particularly weight loss and cardiovascular risk management, rather than medication.

What Is Fatty Liver Disease and How Is It Treated?

Fatty liver disease, medically termed hepatic steatosis, occurs when excess fat accumulates in liver cells. The condition is defined as the presence of fat in more than 5% of liver cells (hepatocytes) on histology, or more than 5% liver fat content on MRI. It exists in two main forms: non-alcoholic fatty liver disease (NAFLD), which affects people who drink little or no alcohol, and alcohol-related liver disease (ARLD), caused by excessive alcohol consumption. NAFLD has become increasingly common in the UK, affecting approximately one in three adults, often associated with obesity, type 2 diabetes, and metabolic syndrome. (The term metabolic dysfunction-associated steatotic liver disease, or MASLD, is now also used internationally to describe this condition.)

In many cases, simple fatty liver causes no symptoms and may be discovered incidentally during imaging or blood tests for other conditions. However, some individuals develop non-alcoholic steatohepatitis (NASH), where inflammation and liver cell damage occur alongside fat accumulation, potentially progressing to fibrosis, cirrhosis, or liver failure. Importantly, cardiovascular disease is the leading cause of death in people with NAFLD, making management of cardiovascular risk factors essential.

Current treatment approaches focus primarily on lifestyle modification rather than medication. NICE guidance (NG49) emphasises weight loss as the cornerstone of management. Evidence from clinical trials shows that weight loss of approximately 7–10% of body weight can improve liver fat content, inflammation, and even fibrosis in many patients. This is achieved through:

• Dietary changes: reducing refined carbohydrates, saturated fats, and overall calorie intake

• Regular physical activity: at least 150 minutes of moderate-intensity exercise weekly, as recommended by UK Chief Medical Officers' guidelines

• Managing underlying conditions: optimising control of diabetes, hypertension, and dyslipidaemia to reduce cardiovascular risk

• Avoiding hepatotoxic substances: ideally avoiding alcohol entirely if you have liver disease; if you do drink, stay within the UK low-risk drinking guidelines of no more than 14 units per week, spread over at least three days

Currently, no medications are specifically licensed in the UK for treating NAFLD, though research into pharmacological therapies continues. Management remains focused on addressing the metabolic and cardiovascular factors that contribute to fat accumulation in the liver and overall health risk.

Is Prednisolone Good for Fatty Liver?

Prednisolone is not recommended for fatty liver disease and may actually worsen the condition. (Note: in the UK, prednisolone is the standard oral corticosteroid prescribed; prednisone, which is converted to prednisolone in the body, is rarely used here.) Prednisolone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties, commonly prescribed for conditions such as asthma, rheumatoid arthritis, inflammatory bowel disease, and autoimmune disorders. Whilst it effectively reduces inflammation in many contexts, its metabolic effects make it unsuitable for treating fatty liver.

The pharmacological action of prednisolone involves multiple metabolic pathways that can exacerbate hepatic steatosis. Corticosteroids promote:

• Insulin resistance: reducing the body's ability to utilise glucose effectively

• Increased hepatic gluconeogenesis: stimulating the liver to produce more glucose

• Lipogenesis: promoting fat synthesis and storage

• Redistribution of body fat: encouraging central adiposity

• Hyperglycaemia: elevating blood sugar levels, which can progress to steroid-induced diabetes

These metabolic disturbances directly counteract the therapeutic goals for managing fatty liver disease. Clinical evidence demonstrates that long-term corticosteroid use is associated with worsening hepatic steatosis and can increase metabolic risk in susceptible individuals.

There is no evidence supporting prednisolone as a treatment for fatty liver disease. Patients with existing NAFLD who require corticosteroid therapy for other medical conditions (such as autoimmune hepatitis or severe inflammatory disease) need careful monitoring, including regular checks of weight, blood pressure, blood glucose or HbA1c, lipids, and liver function tests. When corticosteroids are necessary, the lowest effective dose should be used.

If you are currently taking prednisolone or another corticosteroid for another condition and have concerns about fatty liver, it is essential to discuss this with your GP or specialist. Never discontinue prescribed corticosteroids abruptly, as this can cause serious adrenal insufficiency. Any medication changes must be made under medical supervision with appropriate dose tapering. If you are on long-term or high-dose systemic corticosteroids, you should carry a Steroid Emergency Card as advised by the MHRA.

If you experience any suspected side effects from your medication, you can report them via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk.

Alternative Treatments for Fatty Liver Disease

Whilst lifestyle modification remains the primary evidence-based intervention for fatty liver disease, several adjunctive approaches may support liver health and overall metabolic control, though none replace the fundamental importance of weight loss and cardiovascular risk management.

Pharmacological considerations currently focus on managing associated metabolic and cardiovascular conditions rather than directly treating the liver. Medications that may provide benefit include:

• Metformin: this diabetes medication improves insulin sensitivity and is used for glycaemic control in patients with concurrent type 2 diabetes. However, metformin is not indicated to treat NAFLD or NASH itself, as it does not improve liver histology.

• Statins: safe to use in NAFLD patients, including those with mildly elevated liver enzymes, and are important for managing dyslipidaemia and reducing cardiovascular risk, which is elevated in this population. NICE guidance (NG238) supports statin use for cardiovascular disease prevention in people with NAFLD; they should not be withheld solely because of fatty liver.

• Weight-management medicines: NICE-endorsed pharmacotherapy such as semaglutide 2.4 mg (TA876) may be considered as an adjunct to lifestyle interventions for eligible patients with obesity, helping to achieve the weight loss that benefits NAFLD.

• Vitamin E: high-dose vitamin E has been studied in non-diabetic adults with biopsy-proven NASH, but it is not routinely recommended by NICE. It is used off-label only under specialist advice, as potential risks include increased risk of haemorrhagic stroke and other adverse effects. Patients should not self-prescribe high-dose vitamin E.

• Pioglitazone: this thiazolidinedione may improve liver histology in selected patients with biopsy-proven NASH under specialist care, but it is used off-label for this indication. The MHRA has issued important safety warnings regarding pioglitazone, including risks of fluid retention and heart failure, increased fracture risk (particularly in women), and a potential bladder cancer signal. It requires careful patient selection, monitoring, and specialist initiation.

The MHRA and NICE emphasise that no medications are currently licensed specifically for treating NAFLD in the UK, and any pharmacological intervention should be considered only after lifestyle measures have been optimised and under appropriate medical supervision.

Dietary supplements such as omega-3 fatty acids, milk thistle, and various antioxidants are sometimes promoted for liver health. However, robust clinical evidence supporting their efficacy in NAFLD is limited, and they should not substitute for proven lifestyle interventions. Some herbal preparations may even cause liver toxicity.

Bariatric surgery represents an effective option for severely obese patients (BMI ≥40 kg/m² or ≥35 kg/m² with comorbidities such as type 2 diabetes) who have not achieved adequate weight loss through conservative measures. Procedures such as gastric bypass or sleeve gastrectomy can produce substantial, sustained weight loss and significant improvement in hepatic steatosis, inflammation, and even fibrosis. NICE guidance supports bariatric surgery as a treatment option for eligible patients with obesity-related complications including NAFLD.

When to Speak with Your GP About Fatty Liver

Many people with fatty liver disease remain asymptomatic, with the condition often detected incidentally through blood tests showing elevated liver enzymes (ALT, AST, GGT) or imaging performed for other reasons. However, certain circumstances warrant prompt medical consultation.

You should contact your GP if you experience:

• Persistent fatigue or general malaise

• Discomfort or a sensation of fullness in the right upper abdomen

• Unexplained weight loss

Seek same-day or urgent medical attention if you develop:

• Jaundice (yellowing of skin or eyes), especially with fever or feeling systemically unwell

• Dark urine or pale stools

• Easy bruising or bleeding, or vomiting blood

• Swelling of the abdomen or legs that is rapidly worsening

• Confusion or difficulty concentrating (potential signs of hepatic encephalopathy)

• Severe abdominal pain with fever

Risk factor assessment is equally important. You should discuss fatty liver screening with your GP if you have:

• Type 2 diabetes or prediabetes

• Obesity (particularly central adiposity)

• Metabolic syndrome (combination of hypertension, dyslipidaemia, insulin resistance)

• Persistently abnormal liver function tests

• A family history of liver disease

• Polycystic ovary syndrome (PCOS)

• Obstructive sleep apnoea

Initial investigations typically include liver function tests, assessment of alcohol intake, and exclusion of other causes of liver disease such as viral hepatitis (hepatitis B and C), haemochromatosis (ferritin and transferrin saturation), autoimmune liver disease, and medication-related liver injury. Abdominal ultrasound may be arranged to assess liver appearance.

Risk stratification follows the NICE NG49 pathway. Your GP will calculate a NAFLD Fibrosis Score (NFS) or FIB-4 score using your age, BMI, blood test results, and other factors to estimate your risk of advanced liver fibrosis. These scores have different thresholds for people aged 65 and over. If your score is in the indeterminate or high-risk range, your GP may arrange an Enhanced Liver Fibrosis (ELF) blood test where available, or refer you for a FibroScan (transient elastography), a non-invasive scan that measures liver stiffness. These tests help determine whether specialist hepatology referral is needed.

Specialist referral is generally indicated for patients with evidence of advanced fibrosis on risk scores or imaging, those with features of NASH, or when the diagnosis remains uncertain. Early identification and management of fatty liver disease can prevent progression to cirrhosis and, crucially, reduce cardiovascular risk. Your GP can provide personalised advice on lifestyle modification, optimise management of diabetes, blood pressure, and cholesterol, arrange appropriate monitoring, and coordinate care with specialists when necessary.

If you experience any suspected side effects from medications you are taking, you can report them via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk.

Frequently Asked Questions